Kornimate/medical-research-clean huggingface dataset:
a multicenter, random control study :early use of airway pressure release ventilation (aprvplus) protocol in ards

Conditions: Acute Respiratory Distress Syndrome

Summary: animal experimentals have shown that the more physiology-driven airway pressure release ventilation (aprv) methodologies in ards may significantly improve alveolar recruitment and gas exchange, increased homogeneity, and attenuate lung injury, without circulatory depression, as compared with conventional low tial volume lung protective ventilation. our previous single centre,random control study showed that clinical benefit for early use of aprv in ards. nonetheless, clinical data on ards are still limited, most of them derived from small clinical trials in which variable outdated aprv settings were used, consequently, the findings of these studies were controversial. additionally, the previous single-centre,random control study showed that clinical benefit for aprv.therefore,the investigators are ready to design a multiple centres,random control study to further verify the effect of aprv plus protocol in ards.

all the patients included will be randomly assigned to receiving aprv plus protocol or low tidal volume ventilation.

Eligibility criteria:
inclusion criteria: * moderate and severe acute respiratory distress syndrome,according to the berlin definition of ards * receiving tracheal intubation and mechanical ventilation was no longer than 48 hours exclusion criteria: * pregnancy * the expected duration of mechanical ventilation was less than 48 hours * intracranial hypertension (suspected or confirmed) * neuromuscular disorders that are known to prolong the need for mechanical ventilation * known or suspected chronic obstructive pulmonary disease(copd) * terminal stage of disease * pneumothorax (drained or not)at enrollment * treatment with extracorporeal support (ecmo) at enrollment * there was a lack of commitment to life support.
doxapram as an additive to propofol sedation in sedation for ercp

Conditions: Sedation; Hypoxia

Summary: sedation is needed in order to complete endoscopic retrograde cholangiopancreatography (ercp) to alleviate discomfort and pain during the procedure. this is usually achieved with use of opioids and/or sedative agents such as benzodiazepines or propofol. traditionally benzodiazepines have been used but nowadays propofol is becoming the drug of choice for sedation during ercp. the problem with propofol sedation is the fact that it may case cardiorespiratory depression and there is no antidote for this like there is for benzodiazepines. cardiovascular depression can usually be easily counteracted with drugs that are used to raise blood pressure or heart rate during general anesthesia but respiratory depression remains a problem. the aim of this study is to try to counteract the respiratory depression caused by propofol sedation using an old respiratory stimulant doxapram as opposed to placebo using a double blind randomized protocol. the investigators hypothesis is that boluses and an infusion of doxapram will alleviate the respiratory depression caused by propofol sedation.


Eligibility criteria:
inclusion criteria: * \< 75 year of age * having ercp * agrees to take part in the study exclusion criteria: * \>75 years of age * allergy to propofol or doxapram * epilepsy * chronic obstructive pulmonary disease (copd) * coronary artery disease (symptomatic) * alcoholism * declines to take part in the study

Keywords: cholangiopancreatography, endoscopic retrograde sedation
aczone 5% gel as maintenance treatment of acne vulgaris following completion of oral doxycycline and aczone 5% gel

Conditions: Acne Vulgaris

Summary: this pilot study will explore if continuation of treatment of treatment with aczone 5% gel following combination treatment with with doxycycline and aczone 5% gel can maintain therapeutic response.

this is a two-center, open-label pilot study. the study is apprised of 7 study visits: baseline and weeks 4, 8, 12, 16, 20 and 24. all subjects will receive aczone 5% gel bid and doxycycline 100mg by mouth once daily at baseline. those subjects achieving treatment response (i.e., iga of 0, 1 or 2) at week 12 will continue treatment with aczone 5% gel bid at week 12. subjects not achieving treatment response will discontinue study participation.

Eligibility criteria:
inclusion criteria: * outpatient, male or female subjects of any race, age 12 or older. female subjects of childbearing potential must have a negative urine pregnancy test result at baseline and practice a reliable method of contraception throughout the study; * facial acne vulgaris characterized by the following: iga score \>3 10-50 facial inflammatory lesions (papules,pustules) 10-100 facial non-inflammatory lesions (open/closed comedones) * able to understand and comply with the requirements of the study and sign informed consent/hipaa authorization forms exclusion criteria: * female subjects who are pregnant (positive urine pregnancy test), breast feeding, or who are of childbearing potential and not practicing a reliable method of birth control. * allergy/sensitivity to any component of the test treatment (section 5.2), lincomycin, tetracyclines, or sulfites. * subjects who have not complied with the proper wash-out periods for prohibited medications/procedures (supplement 1)\> * history of clinically significant anemia or hemolysis. * history of enteritis (regional enteritis, ulcerative colitis, pseudomembranous colitis, or antibiotic-associated colitis). * skin disease/disorder that might interfere with the diagnosis or evaluation of acne vulgaris * evidence of recent alcohol or drug abuse * medical condition that, in the opinion of the investigator, contraindicates the subject's participation in the clinical study * history of poor cooperation, non-compliance with medical treatment or unreliability * participation in an investigational drug study within 30 days of the baseline visit.
a study of oral upadacitinib (rinvoq) tablets to assess adverse events and change in disease symptoms in korean participants with moderate to severe active rheumatoid arthritis, atopic dermatitis, ankylosing spondylitis or psoriatic arthritis

Conditions: Rheumatoid Arthritis (RA); Atopic Dermatitis (AD); Ankylosing Spondylitis (AS); Psoriatic Arthritis (PsA)

Summary: rheumatoid arthritis (ra) is an inflammatory disease of the joints characterized by the swelling of multiple joints and tenderness caused by progressive inflammatory synovitis, which leads to serious and debilitating diseases. atopic dermatitis (ad) is a skin condition that may cause a rash and itching due to inflammation of the skin. ankylosing spondylitis (as) is a form of chronic arthritis causing inflammation in the spine. this can cause pain and stiffness in the back. psoriatic arthritis (psa) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. it is caused by the body's immune system mistakenly attacking healthy joint tissue causing inflammation, joint damage, disability, and a reduced life expectancy. this study will assess the adverse events and change in disease symptoms in korean participants with ra, ad, as or psa. upadacitinib is a drug approved for the treatment of moderately to severely active rheumatoid arthritis, atopic dermatitis, ankylosing spondylitis or psoriatic arthritis. korean participants who have been prescribed upadacitinib by their physicians will be enrolled. approximately, 3600 participants will be enrolled this study, in multiple sites within korea. participants will receive upadacitinib as prescribed by the physician and will be followed for approximately 28 weeks. there will be no additional burden for participants in this trial compared to their standard of care. participants will attend regular visits during the course of the study at a hospital or clinic and will be asked to provide additional information by questionnaire at each visit.


Eligibility criteria:
inclusion criteria: * adult participants (\>= 19 years of age), atopic dermatitis includes both adolescents (\>= 12 years of age) and adults. * participants suitable for the treatment with upadacitinib according to the approved local label. exclusion criteria: - participants for whom the drug is contraindicated in the approved local label.

Keywords: rheumatoid arthritis atopic dermatitis (ad) ankylosing spondylitis (as) psoriatic arthritis (psa) upadacitinib rinvoq
testing for covid-19 infection in asymptomatic persons

Conditions: COVID-19 Infection

Summary: intensive action has been taken around the globe to fight the corona virus sars-cov-2 (covid-19) pandemia. clinical symptoms of the infection appear to be variable, from basically asymptomatic infections and mild, flu-like symptoms up to severe respiratory insufficiency, requiring mechanical ventilation at the intensive care unit, and death. broad testing for covid-19 infection has been proven difficult in clinical practice and hampered by limited resources. urgently needed epidemiological data on the rate of silent, asymptomatic infections in the population and the percentage of individuals that have already developed immunity are still missing. within this study we therefore plan to (i) determine the proportion of asymptomatic covid-19 virus carriers in (a) german cancer research center (dkfz) employees, who work and are present at the center during the time of extended minimum operation and (b) in all dkfz employees before onboarding when extended minimum operation has been terminated. we plan to (ii) develop a high-throughput assay for covid-19 testing as well as (iii) a serum-based covid-19 antibody assay. finally, we will (iv) analyze for a possible correlation between oral microbiome and covid-19 infection status.


Eligibility criteria:
inclusion criteria: dkfz employee exclusion criteria: non dkfz employee
echocardiographic parameter and sleep apnea changes after mitral valve surgery

Conditions: Sleep Apnea

Summary: the investigators evaluate the changes of echocardiographic and sleep apnea parameters after mitral valve surgery. the patients undergo echocardiographic and sleep apnea control before surgery. after a period of 3-5 months, they undergo a second echocardiographic and sleep apnea control and the results are evaluated.


Eligibility criteria:
inclusion criteria: * mitral valve defect * nyha ii-iv * no additional cardiac surgical procedure exclusion criteria: * pregnancy * lung disease * regular follow-up in the study center in the first 6 months after surgery not guaranteed * congenital heart disease

Keywords: mitral valve valve surgery echocardiography
seizure detection and warning system in epilepsy patients

Conditions: Epilepsy; Generalized Tonic-Clonic Seizures

Summary: this is a phase iii, pilot, prospective study of an electromyography (emg) based seizure detection system for detecting generalized tonic-clonic seizures (gtcs) in the home.

the brain sentinel™ seizure detection and warning system is intended for monitoring children and adults with a history or significant risk of generalized tonic-clonic seizures in the home or healthcare facilities, during the titration or withdrawal of anti-epileptic drugs, and for continuous monitoring (night time or any other time of day) of individuals due to their history or risk of generalized tonic-clonic seizures. the device will withstand activities of daily living including showers and sleep.

Eligibility criteria:
inclusion criteria: 1. subject has a history of gtc seizures, either primary gtc or partial onset seizures with secondary generalization. 2. male or female between the ages of 2-99. 3. has an upper arm circumference which is adequate for proper fit of the emg monitor (at least 14cm). 4. be able to tolerate wearing the device on the upper arm. 5. if female and of childbearing potential, has a negative pregnancy test. 6. can understand and sign written informed consent, or will have a parent or a legally authorized representative (lar) who can do so, prior to the performance of any study assessments. 7. subject and/or primary caregiver must be competent to follow all study procedures. 8. is able to read, speak and understand english. exclusion criteria: 1. does not have a documented history of generalized seizures. 2. the subject's upper arm circumference not adequate for proper fit of the emg monitor (less than 14cm) 3. pregnant female 4. subject/caregiver is unable to provide consent. 5. subject/caregiver is not competent to follow home study procedures. 6. the subject is homeless or in a home without a power supply.
biolux p-i first in man study

Conditions: Atherosclerosis; Arteriosclerosis; Vascular Disease; Peripheral Artery Disease

Summary: a prospective, multi-centre, randomized controlled, first in man study to assess the safety and performance of the coated passeo-18 lux paclitaxel releasing pta balloon catheter vs. an uncoated balloon catheter in patients with stenosis and occlusion of the femoropopliteal arteries.


Eligibility criteria:
inclusion criteria: 1. age ≥ 50 years, 2. informed consent signed by patient prior to randomization 3. single or sequential de novo or restenotic lesions (stenosis ≥ 70% diameter reduction or occlusion) in the femoropopliteal arteries ≥ 30 mm and ≤ 200 mm long 4. rutherford class 2 - 5 in the target limb 5. reference vessel diameter (rvd) 3 - 7 mm, based on visual estimation 6. inflow free from flow-limiting lesion (\ 50% stenosis) can be included if lesion has been treated successfully before the index procedure 7. at least one non-occluded crural vessel (eg without significant stenosis) with angiographically documented run-off to the foot 8. successful wire crossing of the lesion 9. willingness to comply with all specified follow-up evaluations 10. male or negative pregnancy test of women in childbearing age exclusion criteria: 1. co-morbid conditions limiting life expectancy ≤ 1 year 2. patient currently participating in another clinical trial 3. lesions which are untreatable with pta or other interventional techniques 4. the target stenosis is located distal to a stenosis ≥ 50% that cannot be pre-treated because the drug coating could get lost during crossing the proximal lesion 5. thrombus in the target vessel, documented by angiography 6. target lesion is severely calcified, documented by angiography 7. prior bypass surgery of target vessel 8. previously implanted stent in the target lesion 9. treatment of bifurcation required 10. planned amputation of the target limb 11. flow-limiting (\> 50% ds) inflow lesion proximal to target lesion, left untreated 12. failure to obtain \ 50% ds) inflow lesion in the ipsilateral iliac or proximal sfa. (deb or des not allowed for the treatment of inflow lesion) 13. additional hemodynamically relevant proximal and distal lesions with stenosis ≥ 50 %, except iliac arteries, are excluded. iliac artery lesion treatments have to be successful with a residual stenosis ≤ 30 % 14. haemorrhagic diathesis or another disorder such as gastrointestinal ulceration or cerebral circulatory disorders which restrict the use of platelet aggregation inhibitor therapy and anticoagulation therapy 15. phenprocoumon intake 16. impaired renal function (creatinine ≥ 2.0 - 2.5 mg/dl), according to investigator assessment 17. known allergy to contrast media that cannot be adequately controlled with pre-medication 18. allergy, intolerance or hypersensitivity to paclitaxel structurally or related compounds and/or to the delivery matrix n-butyryl tri-nhexyl citrate (bthc)

Keywords: stenosis occlusions sfa pta poba drb
massage therapy for chronic low back pain

Conditions: Low Back Pain

Summary: the purpose of this study is to determine whether massage is effective in the treatment of low back pain and to optimize clinical therapeutic schedule of massage for low back pain.

chronic low back pain is a prevalent condition among adults. large majority of the population suffer from chronic low back pain in their lifetime. at present, there is still no standard treatment for chronic low back pain. massage is commonly chose and widely used by sufferer as a complement to conventional treatment. however, its effectiveness is still not convinced. this trial is designed to assess the effectiveness of massage for chronic low back pain.

Eligibility criteria:
inclusion criteria: * in accordance of the diagnostic criteria of low back pain; * age between 20 and 55 years old; * not taking hormone drugs or antirheumatic drugs within the latest 2 months; * no allergy history of hormone drugs pain medicine; * volunteer participation and signing an informed consent in writing. exclusion criteria: * being pregnant or during lactation; * having suffered from serious psychiatric, neurologic, cardiovascular, respiratory, or renal illnesses, and so forth; * severe neurological deficits caused by severe lumbar disc protrusion, and operation indications; * receiving message therapy in past 3 months for releasing low back pain.

Keywords: massage low back pain
comparison of relapse rate after 12 weeks verses 20 weeks steroid therapy for the management of first episode of steroid sensitive nephrotic syndrome

Conditions: Steroid-Sensitive Nephrotic Syndrome

Summary: all children from 1 to 8 years of age, diagnose with nephrotic syndrome for the first time will be divided into two groups. one group will be given steroids for 12 weeks and other group will receive steroid for 20 weeks. during the 1 years after completion of steroid course patients will be monitor for the episodes of relapse in both group.

all children from 1 to 8 years of age, diagnose with nephrotic syndrome for the first time, at pakistan institute of medical sciences, islamabad, from december 2020 to december 2022 will be included in the study. sample size was calculated by using who sample size calculator keeping level of significance 5%, power of test 90%, p1 21.6%7 and p2 59.3%8. the sample size is turned out to be 34 patients in each group with total of 68 patients. the patients fulfilling the inclusion criteria will be registered at our nephrology clinic. patients' bio data along with history and examination will be recorded on a proforma. they will be divided in two groups designated as a and b. group a will receive steroid for 12 weeks and group b for 20 weeks. for group a regimen will be to administer prednisolone as a single dose of 60 mg/m2 once daily for 6 weeks, then 40 mg/m2 on alternate day for another 6 weeks and then stop. for group b prednisolone will be given as a single dose of 60 mg/m2 once daily for 6 weeks, then 40 mg/m2 on alternate day for another 6 weeks with tapering of 25% of alternate day dose fortnightly. outcome will be measured in terms of number of relapses in the subsequent 1 years after stopping steroids. for treatment of relapse prednisolone will be given in the dose of 60 mg/m2 once daily till urine protein is negative or trace for 3 consecutive days, then 40 mg/m2 on alternate day for 1 month then stop. in case of frequent relapses and steroid dependent cases, relapses will be treated as follows; prednisolone 60 mg/m2 on alternate day till urine protein will be negative for 5days then 40 mg/m2 on alternate day for 1 month then with tapering at the rate of 5 mg fortnightly. children with congenital and infantile nephrotic syndrome, persistent hypertension, gross haematuria, family history of nephrotic syndrome and age below 1 year and above 8 years will be excluded from study. after approval of study from ethical review board, informed consent will be taken from parents. the data obtained will be analyzed using spss version 20. the t test will be applied for comparison of mean and chi sqare test for comparison of percentages. the p value less than .05 will be taken as significant.

Eligibility criteria:
inclusion criteria: * children 1 to 8 years of age, * diagnose with nephrotic syndrome for the first time * steroid sensitive nephrotic syndrome exclusion criteria: * steroid resistant nephrotic syndrome * steroid dependent nephrotic syndrome * syndromic children * children with other co morbidities

Keywords: nephrotic syndrome, steroid response, relapse
venous thromboembolism (vte) knowledge

Conditions: Thromboembolism

Summary: venous thromboembolism (vte) is common especially among post-operative patients, and its occurrence is associated with significant morbidity and mortality. vte is highly preventable with prophylactic modalities ranging from conservative measures such as early mobilization, to mechanical prophylaxis such as intermittent pneumatic compression (icp), to pharmacological prophylaxis such as peri-operative anticoagulation. despite established guidelines from various professional societies, the practice of vte prophylaxis varied greatly from institute to institute. evidence suggests that there is a significant gap between the optimal thromboprophylaxis as suggested by experts and real-work practice. many healthcare-providers (hcp) and patients at risk of vte are either not aware of the risk of vte or not confident to apply the necessary thromboprophylaxis. the knowledge level of vte appears to play a key role in affecting the level of compliance to the optimal thromboprophylaxis. considerable improvement in vte prophylaxis utilization may result from the implementation of a multifaceted educational program. by improving patient's awareness on vte prophylaxis, the incidence of dvt might be reduced. the knowledge level of patients can be improved by various means including educational video, administrative measures, or continue medical education program. however, no prospective study has been performed to assess the impact of an educational program on the vte knowledge level among post-operative patients and their hcp, and if any improvement of their knowledge level can be translated to a better adherence to vte prophylaxis guidelines. we therefore propose to conduct a prospective non-randomized controlled study to evaluate the effect of an education materials for the patients as well as their hcp on their knowledge level as well as the utilization and adherence of vte prophylaxis in these patients by comparing two groups of patients and hcp.


Eligibility criteria:
inclusion criteria: * capable of providing written informed consent and willing and able to adhere to all protocol requirements * male or female at least 18 years of age at the time of providing written informed consent * adult patients age \>18 scheduled for surgical operations * healthcare providers directedly involve in patients care of these surgical patients. exclusion criteria * unable to make their own informed consent * unable to understand the study protocol * visually or auditorily impaired.
serum ghrelin in polycystic ovary syndrome

Conditions: Polycystic Ovary

Summary: measuring serum gherlin in polycystic ovary syndrome patients and compare it to healthy levels

two groups one healthy and other with pco measure ghrelin level in both of them to find relation between pco and ghrelin

Eligibility criteria:
inclusion criteria:pco women * at least 12 months of infertility. * patients with polycystic ovarian syndrome according to rotterdam criteria: exclusion criteria: * patients with hyperprolactinemia * patients with cushing's syndrome * patients with congenital or non-classical adrenal hyperplasia * patients with hormone secreting tumors. * patients with hormonal treatment in the last 3 months.